ReviewCell and tissue research2026
Panx1 and drug discovery: from non-specific inhibitors to tailored drug compounds.
Review in Cell and tissue research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- From channels to communication networks: a perspective on connexins, pannexins and innexins.Cell and tissue research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pannexin (Panx)-1-mediated ATP release has been associated with a broad range of pathological conditions. Conversely, the use of Panx1-inhibitors has shown promising results in the medication of diseases, such as neuroinflammation, melanoma and epilepsy. In addition, Panx1-inhibitors are an indispensable tool for the elucidation of both structure and physiology of Panx1. Over the past years, numerous applications of Panx1-inhibitors have led to new insights into Panx1 influences in health and disease. The major drawback of conventional Panx1-inhibitors, however, is the lack of selectivity resulting in undesired side effects. Nevertheless, these inhibitors are useful resources for drug discovery and lead optimisation approaches have therefore found their way into Panx1 research. Newly developed inhibitors show both high efficacy and selectivity. The combination of drug development and molecular dynamics simulations is a powerful tool to further elucidate both structure and gating mechanisms of Panx1.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.